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Highlights 
  Out of a total of 108 measures identified, only eight were appropriate for use with 
people with ID. 
  Screening tools are available to assess AED side effects in general adult populations; 
there are only two measures specifically designed for use in ID populations. 
  The focus of these measures is broader than side effects and so may not pick up the 
full range of side effects of importance in this group. 
  Side effects of AEDs are inconsistently and inadequately measured in ID populations 
and are overly reliant on carer report. Overall side effect burden is therefore likely to 
be under-reported.  
  There is a clear lack of established and validated assessment scales for patients with ID 
and epilepsy. 
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1. Introduction 
The prevalence of epilepsy in adults with an intellectual disability (ID) is up to 20 times greater than 
in the general population [1]. A recent survey of carers and professionals showed considerable 
concern over presence and impact of side effects from anti-epileptic drug (AED) treatment in people 
with ID (in particular drowsiness, memory problems, depression) [2] . The term side effect typically 
relates to any secondary undesirable effect of a treatment or drug. Physical, cognitive, behavioural or 
emotional side effects can cause significant impact on the quality of life of an individual. Monitoring 
side effects in adults with ID and epilepsy is challenging due to the commonly co-existing 
occurrence of behaviour and communication disorders [3]. The incidence of side effects is estimated 
to be as high as 58% in the wider population receiving treatment (i.e. adults with epilepsy without 
ID) [4]. Javed (2015) noted that patients with ID were less likely to report side effects than patients 
without ID, especially in regard to cognitive adverse events [5]. A recent Cochrane review concluded 
that side effects in the ID population are similar to the general population, however the authors note 
that this is concluded from limited studies with unreliable measures [6].  
 
The importance of Patient Reported Outcome Measures (PROMs) in assessing health status is 
increasingly acknowledged, both in research and in the evaluation of routine clinical care. In a report 
published in 2009 [7], the Medical Research Council (MRC) suggest several key areas for future 
research, including addressing gaps in currently available PROMs, such as for use at end of life and 
in children. However, the gap in available PROMs for use with adult ID populations and their 
families/carers would seem to be greater still. Screening tools are available to assess AED side 
effects in the general adult population, and research suggests that active monitoring is sufficient to 
change management and improve quality of life (QoL) [8]. It is not known however whether such 
tools can be used to identify side effects in adults with ID, or whether included items are important 
and relevant to patients and carers. The importance of developing PROMs that are reliable, valid and 
sensitive to change within the context of clinical trials has also been highlighted [9] and 
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specification, selection and measurement of appropriate outcomes is central to all stages of the MRC 
guidance on complex intervention development [10]. However, a Cochrane review concluded that 
the measurement of side effects in this population was hampered by reliability of available measures 
[11]. In addition those with ID (and individuals with low literacy levels) are often excluded from the 
PROMs development process [9]. Therefore measures may not be accessible or acceptable to this 
population and are likely therefore to produce unreliable data if poorly completed. This group is 
therefore at risk of exclusion from routine patient monitoring and quality improvement schemes thus 
increasing potential health inequalities [9]. 
 
The aim of this focused review is to identify literature on the measurement and impact of AED side 
effects in adult ID populations. Specifically, we wanted to determine whether side effects and their 
impact were being measured, and if so by what methods including whether self- or observer-reported 
and the nature of domains assessed. However, given that development of measures specific to this 
population has received little attention to date, we will also seek to identify measures of AED side 
effects in the wider adult epilepsy population that may be suitable for adaptation in ID populations. 
Results relating to identified side effect domains (e.g. adaptive functioning, cognitive symptoms) 
will be summarised according to population, medication type and AED/QoL measures where the 
data allow. This review forms part of a wider study which aims to develop a psychometrically sound 
measure of AED side effects that professionals can use in consultations with patients and carers to 
identify the important side effects of anti-epileptic drug (AED) treatment in adults with intellectual 
disability.  
  
2. Methods 
 
2.1 Study eligibility criteria 
Selected studies met the following inclusion criteria:  
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 Adults with epilepsy (and an identified subset with ID) 
 Participants were taking at least one AED as part of their treatment regime 
 Side effect outcome measure included  
 Qualitative or quantitative data 
 Articles published in English only.  
 
Side effect outcome measures as stated in the methods section of the paper included, but were not 
limited to the following domains: seizure severity/frequency; psychiatric symptoms; social function; 
cognitive functioning; challenging behaviour; mood; quality of life; physical symptoms. 
 
Studies were excluded if the seizure disorder occurred as a side effect of medical treatment or was 
not specified as epilepsy. Papers were excluded where no outcome data had been published. Papers 
reported from on-going studies which may be relevant (e.g. some feasibility / qualitative 
investigation of side effects which then informed outcome assessment) were included. For the full 
list of search terms see Appendix A. 
 
2.2 Information Sources 
Research articles were identified from MEDLINE In-Process, MEDLINE, EMBASE, SCOPUS and 
Web of Knowledge. We did not stipulate a date restriction. The search resulted in findings from; 
MEDLINE In-Process; 1946, MEDLINE; 1946, EMBASE; 1947, SCOPUS; 1945 and Web of 
Knowledge; 1950 all finishing in May 2015. We did not however search contact authors for any 
unpublished data. 
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2.3 Search strategy 
Appropriate keywords were used e.g: epilepsy, anti-epileptic drug, anticonvulsants, outcome 
measures/ment, scales, side effects, tolerability, seizure severity and frequency, psychiatric, 
cognition challenging behaviour, mood and quality of life (for details of the full search strategy see 
Appendix A). Each search term was classified under one of 4 categories: participants, medication, 
measures and side effect domains, which were combined (requiring all four domains to be included) 
in the database searches.  
 
2.4 Data collection 
Identified papers (n=462) were assessed independently by two researchers and checked for eligibility 
of abstract and title according to the inclusion and exclusion criteria (see Appendix A). Studies that 
met inclusion criteria (n=153) were obtained in full text and again checked for eligibility against the 
same criteria by one researcher. 40% were double checked independently for eligibility by a second 
researcher. Any disagreements identified were reviewed by both researchers and discussed to resolve 
differences. 95 eligible papers were included in the review.  
 
2.5 Data extraction 
A data extraction spreadsheet was created based on the research question. The data extraction fields 
included recruitment data, epilepsy and ID diagnosis, outcome measure and who completed the 
measure. The data extraction sheet was piloted and minor amendments made prior to being finalised. 
 
2.6 Data synthesis 
Each paper was summarised descriptively in terms of AED type, side effect domain, AED/QoL 
measures and who rated the measure (i.e. patient, carer/professional, proxy). Due to the nature of the 
review aim, it was not possible to carry out a meta-analysis and a narrative synthesis was performed 
instead to summarize the outcome measures. Narrative synthesis is a systematic review and synthesis 
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of multiple studies that is summarized in text format. The review had originally aimed to include a 
meta-analysis looking at associations between side effects and other important outcomes e.g. 
psychological well-being and challenging behaviour however no such data were reported. 
 
3. Results 
The initial search via electronic databases yielded 494 records and an additional 36 records were 
identified through hand searching. Subsequent removal of duplicates resulted in 462 papers 
remaining (see Figure 1). Following independent review by two researchers of the abstracts 
according to the inclusion and exclusion criteria 153 studies were included for full paper review. 
From this selection 95 studies were identified as suitable for inclusion for the purposes of review.  
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Figure 1: Diagram of review studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching 
(n =  494) 
Sc
re
en
in
g 
In
cl
ud
ed
 
 
El
ig
ib
ili
ty
 
Id
en
tif
ic
a
tio
n 
Additional records identified 
through other sources 
(n =  36) 
Records after duplicates removed 
(n =  462) 
Records screened 
(n =  462) 
Records excluded (n=307) 
Populations not relevant (n = 171) 
Research ques/intervention not 
relevant (n= 119) 
Book chapter (n=3) 
Protocol only (n=2) 
Excluded for other reasons (n=12) 
 
Full-text articles assessed 
for eligibility 
(n = 155) 
Full-text articles excluded (n=60) 
Research questions/interventions 
not relevant (n = 2) 
Conference papers with no outcome 
data (n=2) 
No outcome measures (n=56) 
Studies included in the 
narrative synthesis 
(n =  95) 
Copeland et.al     9 
 
 
 
3.1 Summary of studies by side effect domain and measure in general and ID adult epilepsy 
populations 
 
Table 1 presents a summary of studies by side effect domain and measure. The side effects measured 
by the studies range from adverse events, behavioural and cognitive changes, through to sexual 
functioning and quality of life. There are 108 measures used across all the studies. Eleven of these 
measures were used in the ID studies. Of the 108 measures, eight are designed for use with people 
with ID. The majority (51) of the measures for the general adult population were to be rated by the 
participant. This is in contrast to the measures used in the ID studies which were carer-rated. 
 
Table 1: Summary of studies by side effect domain and measure  
Table 1: Summary of studies by side effect domain and measure 
Side Effect 
Domain 
Measure ID 
specific 
Yes/ No 
Rater 
according 
to study 
Paper Reference 
Adaptive 
functioning 
Adaptive 
Behaviour 
Scale - Revised  
(ABS-R) 
Yes Carer Kerr et al (2005) [12] 
Adverse Effects 
 
 
Liverpool 
Adverse Events 
Profile (LAEP) 
No Self Martins et al (2011) [13],  
Zou et al (2014) [14],  
Hakami et al (2012) [15]  
Scale for the 
Evaluation and 
Yes Carer Matson et al (2005) [16]  
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Identification 
of Seizures, 
Epilepsy, and 
Anticonvulsant 
Side Effects-B 
(SEIZES B) 
Adverse Event 
Profile (AEP) 
No Self Maschio et al (2012) [17], 
Villagran et al (2015) [18] 
WHO Toxicity 
Grading Scale 
for 
Determining 
the Severity of 
Adverse Events 
No  Unclear Wu et al (2009) [19] 
Veterans 
Administration 
Cooperative 
study 
(Neurological 
and Systemic 
Adverse Event 
Rating Scales 
[N&SAERS]) 
No Researcher Chmielewska et al (2001) 
[20], 
Chmielewska et al (2013) 
[21] 
Anxiety 
 
Zung Anxiety 
Scale (ZUNG-
No Researcher Ketter et al (1996) [22] 
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ANX) 
Hospital 
Anxiety and 
Depression 
Scale (HADS) 
No Self Gillham et al (2000) [23], 
Hardan et al (1999) [24], 
Martins et al (2011) [13], 
Mosaku et al (2006) [25], 
Nabukenya et al (2014) 
[26],  
Pataraia et al (2013) [27], 
Smith et al (1993) [28],  
Tang  et al (2012) [29], 
Tsounis et al (2011) [30] 
Hamilton 
Anxiety Scale 
(HARS) 
No Self Martinovic et al (2004) [31], 
Mazza et al (2007) [32], 
Mazza et al (2008) [33],  
Tang et al (2012) [29] 
Beck Anxiety 
Inventory 
(BAI) 
No Self Kim et al (2012) [34] 
Behaviour  
 
Matson 
Evaluation of 
Social Skills in 
Individuals 
with Severe 
Retardation 
(MESSIER)  
Yes Carer Martin et al (2009) [35] 
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Aberrant 
Behavior 
Checklist 
(ABC)- Total 
Yes Carer McKee et al (2003) [36], 
Mckee et al (2006) [37], 
Martin et al (2009) [35],  
Sunder et al (2006) [38],  
Kerr et al (2005) [12]  
Behavioural 
adjustment 
Minnesota 
Multiphasic 
Personality 
Inventory-2 
(MMPI-2) 
No Unclear Hessen et al (2008) [39]  
Behavioural 
disturbance 
Whelan and 
Speake Rating 
Scale 
Unclear Unclear Crawford et al (2001) [40]  
Challenging 
Behaviour 
Key Carer-
rated Visual 
Analogue 
Scales 
Yes Carer Crawford et al (2001) [40]  
Cognitive 
 
Mini Mental 
state 
examination 
(MME) 
No Self Wu et al (2009) [19]  
Dementia 
rating scale 
No Self Martin et al (2005) [41]  
Digit Span  
Forward 
No Researcher Kalviainen et al (1995) [42]  
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Korean-
California 
verbal learning 
test (K-CVLT), 
No Unclear Kim, D. et al (2012) [34] 
Stroop Color– 
Word 
Interference 
No Self Lee et al (2011) [43],  
Xu et al (2007) [44] 
EpiTrack No Unclear Lutz et al (2005) [45] 
Wechsler 
memory scale 
No Self Martin et al (2005) [41] 
Montreal 
Cognitive 
Assessment 
(MoCA) 
No Unclear Nakhutina et al (2015) [46] 
Corsi Block 
Span 
No  Self Kalviainen et al (1995) [42]  
Korean-Boston 
naming test (K-
BNT) 
No Unclear Kim, D. et al (2012) [34] 
Controlled oral 
word 
association test 
No Self Martin et al (2005) [35] 
Alternating S 
Task 
No Researcher Kalviainen et al (1995) [42]  
A-B No Unclear Nakhutina et al (2015) [46] 
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Neurotoxicity 
Scale. 
The A—B 
Neuropsycholo
gical 
Assessment 
Schedule 
No Unclear Satischandra et al (2014) 
[47] 
 Rivermead 
Behavioural 
Memory Test 
(RBMT) 
No Researcher Brandt et al (2015) [48] 
 
Cognitive/ IQ Wechsler Adult 
Intelligence 
Scale 
No Self Kalviainen et al (1995) [42],  
Kim et al (2012) [34],  
Lee et al (2011) [43],  
Lutz et al (2005) [45],  
Sun et al (2008) [49], 
Sunmonu et al (2008) [50],  
Xu et al (2007) [44],  
Brandt et al (2015) [48] 
Depression 
 
Beck 
Depression 
Inventory 
(BDI) 
No Self Fakhoury et al (2008) [51], 
Rani et al (2014) [52], 
Villagran,et al (2015) [18], 
Mazza et al (2007) [32],  
Cho et al (2011) [53],  
Martinovic et al (2004) [31]  
Copeland et.al     15 
 
 
 
Hamilton 
Depression 
Scale (HAM-
D) 
No Self Martinovic et al (2004) [31],  
Mazza et al (2007) [32], 
Mazza et al (2008) [33]  
Neurological 
Disorders 
Depression 
Inventory for 
Epilepsy 
(NDDI-E)  
No Self Rathore et al (2013) [54], 
Fakhoury et al (2008) [51], 
Ettinger et al (2014) [55], 
Williams et al (2011) [56]  
Global 
assessment of 
severity of 
epilepsy 
(GASE) scale 
No Unclear Wiebe et al (2014) [57] 
Cornell 
Dysthymia 
Rating Scale-
Self-Report 
(CDRS) 
No Self Hardan et al (1999) [58], 
Mazza et al (2007) [32], 
Martinovic et al (2004) [31]  
Patient Health 
Questionnaire 
(PHQ-9) 
No Unclear Rathore et al (2013) [54]  
Center for 
Epidemiologic 
No Self Ettinger et al (2014) [55], 
Mei (2006) [59]  
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Studies 
Depression 
Scale (CES-D)  
 
Geriatric 
Depression 
scale 
No Self Martin et al (2005) [41] 
Disability Global 
Assessment of 
Epilepsy-
Related 
Disability 
(GAERD)  
No  Unclear Sajobi et al (2014) [60]  
Functionality 
 
Crichton Royal 
Behavioural 
Rating Scale 
No Unclear Crawford et al (2001) [40]  
Habilitative 
Improvement 
Scale 
No Carer McKee et al (2003) [36], 
McKee et al (2006) [37], 
Sunder et al (2006) [38] 
 
Health 
 
General Health 
Questionnaire 
(GHQ-28) 
No Self Gillham et al (1993) [61]  
Patient Health 
Questionnaire-
9 (PHQ-9) 
No Self Tesar et al (2011) [62]  
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Mental Health 
Inventory(MHI
-5)  
No Unclear Wagner et al (1995) [63]  
Quality of life SEALS Side 
Effects and 
Life 
Satisfaction 
inventory 
No Self Gillham et al (1996) [4], 
Gillham et al (2000) [23], 
Leach et al (1997) [64]  
Profile of 
Mood States 
(POMS) 
No Self Ettinger et al (2007) [65], 
Fakhoury et al (2008) [51], 
Gillham et al (2000) [23] 
(Validation paper), 
Nakhutina et al (2015) [46],  
Salinsky et al (2005) [66], 
Smith et al (1993) [67] 
(Outcomes paper),  
Smith et al (1993) [28] 
(Seizure paper) 
Quality of Life 
Assessment 
Schedule 
(QOLAS) 
No Unclear Kaiser et al (2002) [68]  
Epilepsy 
Outcome Scale 
(EOS)  
Yes Researcher Kerr et al (2005) [12]  
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Epilepsy and 
Learning 
Disabilities 
Quality of Life 
(ELDQoL) 
Yes Researcher Kerr et al (2005) [12] 
EORTC-QLQ-
C30 
No Unclear Maschio et al (2012) [17]  
15D HRQoL 
instrument 
No Self Stavem et al (1998) [69]  
Medical 
Outcomes 
Study - 
Cognitive 
Functioning 
(MOS-COG) 
No Self Gillham et al (2000) [23] 
(Validation paper),  
Nottingham 
Health Profile 
(NHP) 
No Self Smith et al (1993) [67] 
(Outcomes paper),  
Smith et al (1993) [28] 
(Seizure paper) 
TTO (Time 
Trade Off 
method)  
No Self Stavem et al (1998) [69]  
 
 
 
Visual 
Analogue Scale 
(VAS) 
No Unclear Chmielewska et al (2001) 
[20],  
Jozwiak et al (2000) [70], 
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Villagran et al (2015) [18]  
Quality of Life 
in Epilepsy 89 
(QOLIE-89) 
No Self Engel et al (2012) [71],  
Hakami et al (2012) [15]  
Quality of Life 
in Epilepsy-
Problems 
(QOLIE-31-P) 
No Self De Backer et al (2012) [72], 
Dunlap et al (2014) [73], 
Anders et al (2015) [74],  
Heo et al (2007) [75]  
 
Quality of Life 
in Epilepsy 
(QOLIE-31) 
No Self Marson et al (2007) [76], 
Maschio et al (2012) [17], 
Mosaku et al (2006) [25], 
Nabukenya et al (2014) 
[26],  
Fritz et al (2005) [77],  
Heo et al (2012) [78], 
Zou et al (2014) [14]  
 
Quality of Life 
in Epilepsy 
(QOLIE-10)  
No Self Satischandra et al (2014) 
[47],  
Semah et al (2014) [79]  
Quality of 
Well-Being 
Self-
Administered 
No Self Gao et al (2013) [80]  
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Scale (QWB-
SA) 
WHO Quality 
of Life-Brief 
version 
No Unclear Shaw, D. et al (2015) [81]  
EuroQol 
instrument 
No Self Stavem et al (1998) [69],  
Selai et al (1999) [82]  
Quality of Life 
Questionnaire 
(QOL-Q) 
Yes Self Wang, T. G. et al(2008) [83]  
Short-form 36 No Unclear Baker et al (2002) [84],  
Smith et al (1993) [67], 
Wagner et al (1995) [63],  
Williams et al (2011) [56]  
Quality of Life 
in Epilepsy 48 
(QOLIE AD-
48) 
No Self Engel et al (2012) [71]  
30-item 
General Health 
Questionnaire 
(GHQ-30) 
No Unclear Mosaku et al (2006) [25]  
Medical 
Outcomes 
Survey Short 
No Unclear Semah et al (2014) [79]  
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Form 12 
(SF12)  
Social 
Problems 
Questionnaire  
No Self Smith et al (1993) [67]  
NEWQOL 
(Newly 
Diagnosed 
Epilepsy 
Quality of 
Life) 
No Self Marson et al (2007) [76]  
Modified Mini 
Mental State 
Examination 
(mMMSE) 
No Unclear Mosaku et al (2006) [25]  
Impact of 
Epilepsy (IoE) 
Scale 
No Self Marson et al (2007) [76], 
Satischandra et al (2014) 
[47] 
 
Impulsiveness 
Barratt 
Impulsiveness 
Scale-11 (BIS-
11) 
No Unclear Helmstaedter et al (2008) 
[85]  
Medication 
response 
Side Effect of 
Anti-Epileptic 
Drugs Ques. 
No Self Uijl et al (2009) [86]  
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(SIDAED)  
Mental and 
psychological 
health  
  
Columbia-
Classification 
Algorithm of 
Suicide 
Assessment (C-
CASA) 
No Unclear Biton et al (2015) [87]  
Columbia-
Suicide 
Severity Rating 
Scale (C-
SSRS) 
No Self Biton et al (2015) [87],  
Rani et al (2014) [52]  
Bunney-
Hamburg 
Rating Scale 
No Researcher Ketter et al (1996) [22]  
Mood 
 
Befindlichkeits
-Skala (BFS) 
No Unclear Fritz et al (2005) [77]  
Cornell 
Dysthymia 
Rating Scale—
Self-Report 
(CDRS) 
No Unclear Hardan et al (1999) [58], 
Mazza et al (2007 [32], 
Ettinger et al (2007) [65], 
Martinovic et al (2004) [31]  
Profile of 
Mood States 
(POMS) 
No Unclear Nakhutina et al (2015) [46] 
Salinsky et al (2005) [66], 
Ettinger et al (2007) [65], 
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Gillham et al (2000) [23], 
Fakhoury et al (2008) [51], 
Smith et al (1993) [67]  
Amsterdamse 
Stemmingslyst 
(ASL) 
No Self Aldenkamp et al (1994) [88]  
Montgomery 
and Asberg 
Depression 
Rating Scale 
(MADRS) 
No Researcher Mazza et al (2008) [33]  
Portland 
Neurotoxicity 
Scale (PNS)  
No Unclear Salinsky et al (2005) [66]  
Delighted-
Terrible Scale 
No Self Satischandra et al (2014) 
[47] 
Zung Self 
Rating Scale 
for Depression 
(Z-SDS) 
No Self Mazza et al (2008) [33]  
Personality Fragebogens 
zur 
Persönlichkeit 
bei zerebralen 
Erkrankungen 
No Unclear Helmstaedter et al (2008) 
[85]  
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(FPZ) 
Psychomotor 
performance 
Digit-Symbol 
Substitution 
Test [DSST] 
No Unclear Altman et al (2013) [89]  
Psychopatholog
ical function 
Symptom 
Checklist 90—
Revised (SCL-
90-R) 
questionnaire 
No Self Wu et al (2009) [19]  
Sedation 
 
Stanford 
Sleepiness 
scale 
No Unclear Altman et al (2013) [89], 
Salinsky et al (1996) [90],  
Shah et al (2010) [91]  
Epworth 
Sleepiness 
scale (ESS) 
No Unclear Bonanni et al (2004) [92],  
Cho et al (2011) [53],  
Foldvary et al (2001) [93],  
Shah et al (2010) [91]  
Observer’s 
Assessment of 
Alertness/Sedat
ion Scale 
No Researcher Altman, et al (2013) [89]  
Sedation score No Self Gillham et al (1993) [61]  
Seizure severity 
 
Clinical Global 
Impression of 
Change 
No Self Anders et al (2015) [74],  
Tsounis et al (2011) [30]  
Liverpool No Researcher Baker et al (2002) [84],  
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Seizure 
Severity scale 
(LSSS) 
Tesar et al (2011) [62]  
National 
Hospital 
Seizure 
Severity Scale 
(NHS3) 
No Clinician Cho et al (2011) [53],  
Kaiser et al (2002) [68],  
Peng et al (2014) [94],  
Zou et al (2014) [14]  
Seizure 
Severity Scale  
No Unclear Smith et al (1993) [67]  
Sexual function 
 
Changes in 
Sexual 
Function 
Questionnaire 
(CSFQ) 
No Self/ 
Researcher 
Gil-Nagel et al (2006) [95] 
Arizona Sexual 
Experience 
scale (ASEX) 
No Unclear Luef  (2008) [96],  
Shah et al (2010) [91]  
International 
index of 
Erectile 
Function-15  
No Unclear Shaw, D. et al (2015) [81]  
Sexual Self 
efficacy scale 
for erectile 
No Unclear Shaw, D. et al (2015) [81]  
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functioning 
Sleep 
 
Medical 
Outcomes 
Study (MOS) 
Sleep Scale 
No Self de Haas et al (2007) [97]  
Pittsburg Sleep 
Quality Index 
(PSQI) 
No Unclear Peng et al (2014) [94],  
Cho et al (2011) [53]  
Groningen 
Sleep 
Questionnaire 
(GSQ) 
No Self de Haas et al (2007) [97] 
Symptom 
severity 
 
25-item 
Seizure 
Severity 
Questionnaire 
(SSQ) 
No Self Ettinger et al (2014) [55]  
Global 
Evaluation 
Scale (GES)  
No Researcher Heo et al (2007) [75],  
Heo et al (2012) [78]  
Well Being 
 
SEALS Side 
Effects and 
Life 
Satisfaction 
inventory 
No Self Gillham et al (1996) [4], 
Gillham et al (2000) [23],  
Gillham et al (2000) [98], 
Leach et al (1997) [64], 
Marson et al (2007) [76]  
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3.2 Summary of studies with a focus on Intellectual Disability 
Within the 95 papers identified as suitable for inclusion, the reviewers found eight studies that 
looked at adults with epilepsy and ID, who were taking an AED and measured side effects using an 
outcome measure. These studies have been grouped by side effect domain and AED type. Five of the 
studies [[35], [37],[38], [85]] examined only behavioural domains. One paper [40] looked at 
behaviour as well as functionality and one paper examined cognitive adverse events [48]. The final 
paper [12] examined both functionality and quality of life. Table 2 summarizes studies identified 
which have a focus on intellectual disability.  
Table 2: Summary of studies with a focus on Intellectual Disability 
Table 2: Summary of studies with a focus on ID 
Side effect 
domain 
Paper  Participants 
(number, 
epilepsy 
diagnosis 
and ID 
diagnosis) 
Type of 
AED 
Measure Results 
Behavioural Helmstaedter 
et al. (2008) 
[85]  
288 patients 
and 43 
patients as a 
control 
group.  
The type of 
epilepsy was 
not specified.  
14 
288 patients 
on 
Levetiraceta
m (LEV) 
and 43 
patients on 
other AEDs 
acting as a 
control 
Fragebogens 
zur 
Persönlichkeit 
bei zerebralen 
Erkrankungen  
Barratt 
Impulsiveness 
Scale-11: BIS-
11 
Negative side 
effects were 
reported more often 
in patients with ID 
than in general adult 
population patients.  
Behavioral changes 
across the sample 
while taking LEV 
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participants 
were 
described as 
being 
‘mentally 
retarded’ 
with 5% 
being in the 
LEV group 
and 14% in 
the control 
group 
group (12% very negative, 
25% negative, 16% 
positive, and 6% 
very positive)  
Martin et al. 
(2009) [35] 
21 patients 
age 4 years 
plus. 
Any type of 
epilepsy or 
seizure.  
A moderate 
to severe ID 
(ICD-10 
classification
: F71, 38%; 
F72, 52%). 
Topiramate Matson 
Evaluation of 
Social Skills for 
Individuals with 
Severe 
Retardation 
(MESSIER).  
Aberrant 
Behavior 
Checklist 
(ABC).   
The ABC and 
MESSIER tests 
indicated small 
improvements in the 
majority of 
behavioral aspects. 
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McKee et al. 
(2003) [36]  
Patients 
aged at least 
12 years of 
age.  
 Epilepsy 
with seizures 
classifiable 
by the 
International 
Classificatio
n of Seizures  
An 
intellectual 
disability 
based on 
Diagnostic 
and 
Statistical 
Manual IV 
(DSM-IV) 
criteria. 
More than 
two-thirds 
were 
Lamotrigine Percentage of 
patients with 
reductions in 
seizure 
frequency. 
Aberrant 
Behavior 
Checklist  
Habilitative 
Improvement 
Scale. Adverse 
events 
Majority 
improvements in 
seizure frequency, 
duration and 
intensity. 
 
No improvement or 
change in adverse 
events.  
 
No change found 
relative to baseline 
for most patients 
with regards to 
intellectual and 
motor functioning.  
 
Mean ABC scores 
for lethargy and 
stereotopy showed 
significant 
improvement,  
 
Mean Habilitative 
Improvement Scale 
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severely or 
profoundly 
‘mentally 
retarded’. 
scores showed 
significant 
improvement.  
 
Adverse events 
were reported in at 
least 5% of patients 
and included 
somnolence, 
dizziness, ataxia and 
emotional change. 
                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
McKee et al.
(2006) [37]  
Patients 
aged 12 to 20 
years. 
Refractory 
epilepsy.  
An 
intellectual 
disability 
classifiable 
by the DSM-
IV criteria. 
64% had a 
classification 
Lamotrigine Aberrant 
Behaviour 
Checklist 
Habilitative 
Improvement 
Scale 
Adverse events 
and seizure 
counts were 
recorded by 
caregivers 
throughout the 
60% of participants 
noted a 50% 
reduction in seizure 
frequency, 45% 
reported a 75% 
reduction, and 25% 
of participants 
reported zero 
seizures.  
The mean score on 
the Habilitative 
Improvement Scale 
improved 
Copeland et.al     31 
 
 
 
 
 
of severe or 
profound 
‘mental 
retardation’. 
study. significantly from 
baseline.  
Improvements in 
all 5 subdomain 
areas of the Aberrant 
Behavior Checklist.  
80% of participants 
did not experience 
any clinically 
relevant change in 
adverse effects.  
Dizziness, 
somnolence, and 
abdominal pain were 
infrequently 
reported. Vomiting 
was the most 
common adverse 
event.  
 
 
 
 
 
Sunder et al. 
(2006) [38]  
67 
participants 
aged at least 
12 years of 
Lamotrigine Aberrant 
Behavior 
Checklist  
Habilitative 
a reduction in 
seizure frequency, 
duration and 
intensity for most 
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age  
A epilepsy 
diagnosis 
with seizures 
classifiable 
by the 
International 
Classificatio
n of Seizures.  
Mild, 
moderate, 
severe or 
profound 
‘mental 
retardation’ 
based on 
DSM IV 
criteria. 
Improvement 
Scale. 
 Seizure counts 
by type of 
seizure were 
recorded by 
caregivers.  
Adverse events 
recorded by 
caregivers.  
 
patients.  
81% of participants 
in institutional 
settings and 64% in 
community settings 
did not experience 
any change in 
adverse events.  
The mean 
Habilitative 
Improvement Scale 
scores reflected 
improved 
functioning amongst 
the community 
based participants 
however the mean 
score was 
significantly 
improved in relation 
to the baseline phase 
for both groups of 
participants.  
Lethargy, 
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stereotypy, 
hyperactivity and 
inappropriate speech 
ABC domain scores 
were found to be 
significantly 
improved for the 
community based 
group.   
No differences 
were found in any 
ABC domains for 
the group residing in 
institutional settings.  
Behavioural 
and 
function-
ality 
domains 
Crawford et 
al. (2001) 
[40]  
Participants 
aged 12 
years and 
over  
 
Participants 
were 
diagnosed 
with 
localisation-
Gabapentin 
and 
Lamotrigine 
Key Carer-
rated Visual 
Analogue Scales  
Whelan and 
Speake Rating 
Scale  
Crichton Royal 
Behavioural 
Rating Scale  
The results showed 
no difference 
between groups on 
the Visual Analogue 
Scales; 
Both drugs seemed 
to reduce 
challenging 
behaviour as rated 
by Whelan and 
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related 
epilepsy.  
 
An 
intellectual 
disability and 
met the 
DSM-IV 
criteria for 
‘mental 
retardation’ 
on a range of 
levels.  
Physician’s 
Global Rating 
Scale. 
 
Speake Rating 
Scale.  
Functionally 
improved 
significantly with 
gabapentin 
compared to 
lamotrigine as rated 
by the Crichton 
Royal Behavioural 
Rating Scale.  
The Physician’s 
Global Rating Scale 
showed statistically 
significant 
improvements over 
baseline (P < 0.01) 
for challenging 
behaviour, seizure 
severity and general 
health for both 
treatment groups. 
Function-
ality and 
Kerr et al. 
(2005) [12]  
74 
participants 
Topiramate Adaptive 
Behaviour Scale  
Adverse events 
reported were 
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quality of 
life domain 
aged 12 
years and 
older.  
A diagnosis 
of epilepsy  
An 
intellectual 
disability 
defined as an 
IQ of <70 
(classified in 
accordance 
with the 
International 
Classificatio
n of 
Seizures). 
Aberrant 
Behaviour 
Checklist  
Epilepsy 
Outcome Scale  
Epilepsy and 
Learning 
Disabilities 
Quality of Life  
mainly those 
expected from 
people with epilepsy 
who were treated 
with Topiramate as 
add on therapy. 
 Placebo-treated 
patients reported 
nervousness as a 
side effect whereas 
patients on 
Topiramate reported 
somnolence.  
 No significant 
change in reported 
behaviour between 
the Topiramate and 
placebo groups.  
 The quality of life 
measures did not 
indicate any 
significant decline in 
quality of life.  
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Cognitive 
domain 
Brandt et al 
(2015) [48] 
26 
participants  
A diagnosis 
of epilepsy 
and ID 
An 
intellectual 
disability 
assessed 
according to 
ICD-10 
criteria 
Topiramate Rivermead 
Behavioural 
Memory Test  
Digit Span 
Forward and 
backward task / 
Digital symbol 
test (HAWIE-R) 
Regensburger 
Wortflussigkeitst
est (RWT) 
 
Trail Making 
Test (D-KEFS) 
All tests except 
digit span backward, 
naming test and 
RWT (letter B) 
showed significant 
differences on and 
off TPM, indicating 
an impairment of 
cognitive 
functioning by TPM 
in patients with ID 
Attention, speed, 
verbal short term 
memory and verbal 
fluency were 
affected  
 
All of the above studies investigate the effectiveness of specific AED drugs on participants with 
epilepsy and ID. The studies report the efficacy of the AED and any side effects. Several AEDs are 
examined and there are a mixture of results in terms of efficacy and side effects. Some of the studies 
report improvements within side effect domains [[16], [17], [18], [20]]  whilst other studies showed 
no or little improvement [ [35], [82], [85] ] .  
 
The studies use the various measures to investigate behaviour, functionality, cognitive and quality of 
life domains, however, studies also recorded adverse events. One study [35] reported 57 treatment-
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emergent adverse events (TEAEs) in 21 of the 29 patients from a safety cohort (72.4%) during 
treatment. Gastrointestinal disorders and nervousness/restlessness (4 of 29 safety set patients) and 
tiredness/sedation/adynamia, ear/nose/throat infections, injuries, and mental state disorders (3 
patients each) were the adverse effects captured most frequently [35]. Further studies [[12], [36], 
[37], [38]]  also reported adverse events deemed to be drug-related including somnolence, dizziness, 
ataxia, emotional change and vomiting. Therefore although there are a number of measures which 
focus on side effects it is also noted that adverse event recording is an alternative way of 
capturing information about side effects as opposed to using specific outcome measures.  
 
Helmstaedter et al.(2008) [85] suggest that patients with ID reported negative side effects more often 
than patients with normal development. This highlights the need for a measure of AED side effects 
for those with ID. According to the authors of the other studies [[35], [36], [37], [38]] identified in 
this review, ABC, MESSIER and Habilitative Improvement Scale scores are sensitive to change. 
Crawford et al. (2001)[40] stated that although they found no difference between the groups in their 
study for challenging behaviour, functioning did improve significantly with Gabapentin compared to 
Lamotrigine. Both groups showed statistically significant improvements over baseline (P < 0.01) for 
challenging behaviour, seizure severity and general health. The same study also found no significant 
change in reported behaviour between the Topiramte and placebo groups, using a specific behaviour 
change measure. Concurrently the quality of life measures did not indicate any significant decline in 
quality of life.  From these results there appear to be no significant side effects from the intervention 
AEDs, although this may reflect the choice of measure or proxy-assessment, rather than the absence 
of any negative effects. 
 
Side effects and adverse events were assessed within each study using variable methods. For 
example Crawford et al (2001) [40] recorded seizure occurrences in diaries and safety and 
tolerability were assessed by adverse event reports, however it is not noted who completed these 
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diaries or reports (i.e. if they were completed by the participant or the carer). Minimal details 
regarding method of recording adverse events and seizure occurrence are included within the method 
sections of these papers. For example, Sunder et al (2006) [38] notes that adverse events and seizure 
occurrence were recorded by caregivers however no further details are available on the formats used 
to collect this data. There were no studies which included self-reported measures of seizure 
occurrence or adverse/side effects. 
 
The functionality domain measures included in this review were the Adaptive Behaviour Scale 
(ABS-R) [99], the Habilitative Improvement Scale [100] and the Crichton Royal Behavioural Rating 
Scale [101]. The ABS-R and Habilitative Improvement Scale were again carer rated, in the studies 
reported. The Habilitative Improvement Scale and Crichton Royal Behavioural Rating Scale are 
recommended for carer-completion, possibly to provide a more objective assessment of functionality. 
With the exception of the Adaptive Behaviour Scale these measures have not been developed to 
measure functionality in patients with ID. 
 
The final side effect domains noted in these studies were quality of life and cognitive adverse events. 
In relation to cognitive changes Brandt (2015) [48] strongly recommended that these adverse events 
are assessed during the course of treatment, and that the effective assessment of adverse events in 
people with epilepsy is essential as the occurrence of such events has an impact on a persons’ quality 
of life, in patients who are able to follow the instructions established neuropsychological instruments 
may be used.  Quality of Life was measured using the Epilepsy and Learning Disabilities Quality of 
Life (ELDQoL) [102] measure and the Epilepsy Outcome Scale [103]. Both of these measures were 
developed specifically for people with ID to be rated by their carer. Although it is positive these 
measures were developed for the ID population they do not gather the data from the ID patient 
themselves leading to proxy quality of life scores. 
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4. Measures of side effects 
Table 3 outlines side effect measures identified within included studies. The outcome measures 
identified with a focus on behaviour as a side effect domain included Key Carer-rated Visual 
Analogue Scales [20], Matson Evaluation of Social Skills in Individuals with Severe Retardation 
(MESSIER) [104], Aberrant Behavior Checklist (ABC) [105], Barratt Impulsiveness Scale-11 (BIS-
11) [106], Fragebogens zur Persönlichkeit bei zerebralen Erkrankungen (FPZ) and the Whelan and 
Speake Rating Scale [107]. All these measures apart from the Key Carer-rated Visual Analogue 
Scale and the Barratt Impulsiveness Scale-11 (BIS-11), were carer-rated in the reported studies. The 
BIS-11, FPZ and Whelan and Speake Rating Scale were not developed for use in ID populations and 
therefore may not take account of the potential differences in behavioural side effects experienced in 
ID and general adult and elderly epilepsy populations [6].  
 
Table 3: Measures of side effect identified within included studies 
 
Table 3: Measures of side effect identified within included studies 
 
Measure 
 
 
Focus of 
Measure 
Target 
responder 
according 
to study 
Target 
responder 
according 
to 
measure 
 
ID 
specific 
(Yes/No) 
 
Study Reference 
Key Carer-rated 
Visual Analogue 
Scales [40] 
Challenging 
behaviour 
Carer Carer Yes*  Crawford et al. (2001) 
[40]  
Fragebogens zur 
Persönlichkeit bei 
zerebralen 
Personality Carer/self Self No Helmstaedter et al (2008) 
[85]  
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Erkrankungen (FPZ) 
[108]  
Adaptive Behaviour 
Scale- Revised  
(ABS-R) [99] 
Adaptive 
behaviour/ 
functioning 
Carer Carer Yes Kerr et al (2005) [12]  
Matson Evaluation of 
Social Skills in 
Individuals with 
Severe Retardation 
(MESSIER) [104]  
Behaviour Carer Carer Yes Martin et al. (2009) [35] 
Aberrant Behavior 
Checklist (ABC) [105]  
Behaviour Carer Carer Yes Kerr et al (2005) [12] 
Martin et al (2009) [35], 
McKee et al (2003) [36], 
McKee et al (2006) [37], 
Sunder et al (2006) [38]  
Habilitative 
Improvement Scale 
[100] 
Adaptive 
behaviour/ 
functioning 
Carer Carer No McKee et al (2003) [36], 
McKee et al (2006) [37], 
Sunder et al (2006) [38] 
 
Barratt Impulsiveness 
Scale-11 (BIS-11) 
[106] 
Impulsive-
ness 
Carer/self Self No Helmstaedter et al (2008) 
[85]  
Epilepsy Outcome 
Scale (EOS) [103]  
Concerns 
about 
epilepsy 
Carer Carer Yes Kerr et al (2005) [12]  
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Crichton Royal 
Behavioural Rating 
Scale [101] 
Adaptive 
behaviour/ 
functioning 
Carer Carer No  Crawford et al (2001) 
[40]  
Epilepsy and Learning 
Disabilities Quality of 
Life (ELDQoL) [102]  
Health 
related QoL 
Carer Carer Yes Kerr et al (2005) [12]  
Whelan and Speake 
Rating Scale [107] 
Behavioural 
disturbance 
Carer Not 
known** 
Not 
known** 
Crawford et al (2001) 
[40]  
*scale developed specifically for study 
** out of print 
 
5. Discussion 
We chose to undertake a review of the measurement and impact of AED side effects in general and 
adult intellectual disability populations, with a particular focus on results relating to identifying side 
effect measures of AED use (e.g. adaptive functioning, cognitive symptoms) either specifically 
designed for use in ID populations, or that could be adapted for this purpose. We identified 95 
eligible papers, eight of which [[12], [35], [36], [37], [38], [40], [48], [85]] focused specifically on 
ID populations. The side effects measured by the studies range from adverse events, behavioural and 
cognitive, through to sexual function and quality of life. The majority of the measures for the general 
adult population were to be rated by the participant. This is in contrast to the measures used in the ID 
studies which were carer-rated. These findings replicate those of Townsend et al (2012) who 
undertook a systematic review of quality of life measures for people with intellectual disabilities and 
challenging behaviours, reporting that the number of subjective (self-reported) quality of life 
measures appropriate for use by people with intellectual disabilities is limited [109]. Outcome 
measures identified in this review can be broadly categorised within the following side effect 
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domains; behaviour, impulsiveness, functionality, cognitive and quality of life.  
 
The measures identified in this review do not typically contain sufficient and appropriate content to 
identify changes in the overall side effects of AED’s in ID populations. They are generally by-proxy 
measures of behavior or mood change, and as such lack face and content validity in the context of 
drug effects. Reliability and validity of the identified measures are not therefore reported in this 
paper. 
 
The term side effect is defined as: “Any unwanted nontherapeutic effect caused by a drug” [110]. 
Adverse events are defined in Article 2(m) of Directive 2001/20/EC as:   “Any untoward medical 
occurrence in a patient or clinical trial subject administered a medicinal product and which does not 
necessarily have a causal relationship with this treatment” [111].  
 
In the papers identified in this review, the terms “side effect” and “adverse events” are used 
interchangeably throughout. Such side effects or adverse events are seldom focused on in the same 
way and cover a wide range of impacts, for example on adaptive or challenging behaviour or quality 
of life. Side effects and adverse events are generally measured in an ad hoc manner, with no 
standardised way of recording type or frequency of occurrence. In the majority of cases, events are 
carer-reported or the responder is unspecified. Given the methodology otherwise reported, 
particularly if diaries or standardised measures are used, it is likely that assessments are made by 
carers if not otherwise specified.  
 
Studies have also included adverse events reported by participants to the clinician or researcher. 
Furthermore, these adverse events are not explicitly addressed by the outcome measures used by the 
included studies within this review. As the treatment-emergent adverse events referred to above were 
reported voluntarily by participants, these may represent side effects that they were particularly 
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concerned about, were severe or that occurred most frequently.  
 
Thompson (2013) [2] undertook a qualitative study of carer and professional views on the 
management of people with intellectual disability and epilepsy and found that respondents noted a 
number of side effects, but that the impact of these side effects was not well understood by clinicians, 
who in some cases demonstrated a lack of empathy with patients and families. One family member 
noted that including the patient in discussions helps: 
 
“I sometimes feel that a percentage of people taking AEDs would be, on the whole, better off without 
them. Side-effects are often passed off as being unimportant and the recommendation generally is to 
continue increasing a drug. Listening to the patient helps” [2].  
 
Kerr (2009) states that it is important to recognise that the majority of patients in this population are 
unable to self-report side effects and as such there is a tendency for only the more overt side effects 
(such as vomiting or weight gain) to come to the attention of the clinician [3]. Our findings suggest 
that side effects of AEDs are inconsistently and inadequately measured in ID populations, and as 
such are likely to be under-reported. This is consistent with a broader debate reported in the literature 
focusing on the absence of the patients’ voice in drug trials. The adverse events that are reported 
during drugs trials are almost entirely clinicians’ impressions of patients symptoms rather than the 
patients report [112]. Further to this issue a recent review [113] has found the clinician reporting of 
adverse events provides complementary information to patient reported outcome measures. 
Integration of these two measures could improve clinicians and policy makers interpretations of 
clinical trials. It is not known whether currently available PROMs used in the general adult 
population can be used to identify side effects in adults with ID, or whether the items included in 
existing measures are important and relevant to this group of patients and their carers. Furthermore, 
one of the two outcome measures identified that is designed for an ID population, is intended to be 
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rated by carers, and focuses on the more theoretical concept of quality of life (which in practice may 
be poorly defined) rather than on side effects of medication per se. 
 
The results of the current review would seem to support the assertion that patients themselves may 
not be as involved in discussion as they should be, and that outcome measures developed specifically 
for use in adults with epilepsy and ID are either not available or not commonly used. Furthermore, 
clinicians and researchers alike appear to have a preference for using proxy rather than patient 
assessment. However, this may be due to availability of suitable measures. 
 
There are several limitations within this review. In one study [85] only 14 out of 331 participants 
were reported to have had an intellectual disability. However this was taken from patient files and 
not from psychometric evaluations, so the real figure may have been different. Due to these low 
numbers the study may have used different measures more appropriate for the general population 
rather than the ID population. A further limitation of the review is that the grey literature was not 
searched.  
 
The low numbers of studies identified relating specifically to the ID population shows there is a clear 
need for further research in this field. It should also be noted that although the majority of measures 
were not developed specifically for the ID patient population they may nevertheless be useful 
instruments within the clinical setting. Measures are frequently used for research/evaluation purposes 
and so further investigation would be helpful in identifying why such measures are not utilized in the 
clinical environment.  
 
6. Conclusion 
Measurement tools are available to assess AED side effects in the general adult population, however 
as demonstrated by this review there are limited outcome measures designed specifically to be used 
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in ID populations. Furthermore, the focus of these measures is broader than side effects alone, and as 
such they may not be sufficiently in-depth to pick up the full range of side effects of importance in 
this group.  
 
Research suggests that active monitoring of AED side effects in the general adult population is 
sufficient to change management and improve quality of life (QoL) [8]. Therefore, there is a need for 
measures developed specifically to address the potentially different impact of these medications in 
patients with ID, given the high level of comorbidities such as Autistic Spectrum Disorder or mental 
health issues and concomitant medication use, as these are factors which these are factors which also 
need to be considered within the ID population when examining the side effects of AED 
medication.With regards to AED side effects in the ID population Kerr (2009) recommended within 
international consensus guidelines, that baseline cognitive and behavioural assessments should be 
made and then re-measured after drug changes, with validated measures preferred [3]. There is a lack 
of established and validated assessment scales for patients with ID and epilepsy, but the fact that this 
is a heterogenous population and there is a wide range of diversity in communication and cognitive 
deficits, mean it is challenging to develop a scale or measure that is suitable for all. Thornicroft and 
Tansella [114] suggest that important properties for patient based outcome measures are feasibility, 
appropriateness, reliability, validity, responsiveness, precision, 
interpretability and, acceptability. In ID populations, several additional factors should also be 
considered in order for the measure to be truly patient reported such as adaptability for capacity, 
accessibility and length/completion time, to facilitate use in a busy clinical setting. Nevertheless 
there is a clear need to develop a psychometrically sound measure that allows patients with epilepsy 
and ID to self-report the side effects of their AED medication as far as is possible.  
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Appendix A: Search Strategy Evidence Synthesis SIDE-PRO 
Research Question 
What is the measurement and impact of Anti-Epileptic Drug (AED) side effects in general and adult 
ID populations? 
 
PICO 
Participants: general adult population with epilepsy 
Intervention: A measure or scale to measure AED side effects 
Comparison: No comparison 
Measurement: outcome measures/ scales of AED side effects, patient reported outcome measures 
Outcomes: Side effects of AEDs, adverse effects, quality of life, cognitive function and challenging 
behaviour. 
 
Methods 
A search strategy was developed for electronic databases on Ovid Medline using both keywords and 
MeSH headings. The developed search strategy is below. The named anti-epileptic drugs were 
chosen in consultation with medical professionals.  The search strategy was modified to search the 
rest of the databases. 
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MESH and keywords 
Participants 
Epilepsy 
Drugs 
Anti Epileptic Drug 
Anti epilep$ 
AED 
Anticonvulsants 
Felbamate 
Gabapentin 
Lamotrigine 
Levetiracetam  
Oxcarbazepine 
Topiramate 
Vigabatrin 
Zonisamide 
 
 
 
Bibliographic Databases Number of results 
EMBASE 96 
MEDLINE 295 
MEDLINE IN PROCESS 23 
SCOPUS 8 
WEB OF KNOWLEDGE 5 
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Measures 
outcome measures/ment 
scales  
patient reported outcome measures 
 
Outcomes 
side effects 
adverse effects 
tolerability 
Seizure severity and frequency 
Seizure 
Psychiatric 
Social functioning 
cognitive function 
cognitive side effect 
cognition 
memory 
challenging behaviour 
behaviour/al  
behaviour problems 
mood  
quality of life 
 
To be eligible, studies would need to include: 
Adults AND epilepsy (but we want to identify sub-set with LD/ID) AND medication AND side 
effects AND scale/outcome measure. 
